The European Commission (EC) has granted marketing authorisation for AbbVie’s Maviret (glecaprevir / pibrentasvir) to treat adult patients with chronic hepatitis C virus (HCV) infection across all major genotypes (GT1-6).
Go deeper with GlobalData
MAVIRET is a new eight-week, pan-genotypic treatment for patients without cirrhosis and who are new to treatment, comprising the majority of the 71 million people living with HCV worldwide.
The once-daily, ribavirin-free therapy combines 100mg of glecaprevir, an NS3/4A protease inhibitor, and pibrentasvir at 40mg, an NS5A inhibitor, dosed once-daily as three oral tablets.
AbbVie chief scientific officer and research and development executive vice-president Dr Michael Severino said: “Maviret represents an innovation in HCV care as an eight-week, pan-genotypic option that combines two distinct antiviral agents and has high efficacy even against most genotypes commonly associated with resistance to treatment.
See Also:
“This new treatment advancement has the potential to meet the diverse needs of patients in as short as eight weeks across Europe.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn addition, the treatment is indicated for patients with specific treatment challenges, including the ones with compensated cirrhosis across all major genotypes, and those who previously had limited treatment options, such as patients with severe chronic kidney disease (CKD) or those with genotype 3 (GT3) chronic HCV infection.
The EC approval is supported by data from eight registrational studies in the company’s clinical development programme, which assessed more than 2,300 patients in 27 countries across all major HCV genotypes and special populations.
The AbbVie therapy combines two new, potent, direct-acting antivirals that target and inhibit proteins essential for the replication of the HCV.
Glecaprevir (GLE) was discovered during the ongoing partnership between AbbVie and Enanta Pharmaceuticals for HCV protease inhibitors and regimens that include protease inhibitors.
Image: Electron micrographs of hepatitis C virus purified from cell culture. Photo: courtesy of HCV_pictures.png via Wikipedia.
